Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
“Patient interactions between Industry, HTAs,
Academia & Regulators”
The United Parent Projects Duchenne Muscular
Dystroph...
POs Placement in the Medical Development equation
 Grey areas of POs relations with the industry in the past
• Lack of tr...
 Lack of knowledge and skilled expert patients
 Lack of transparency and a common code of conduct
 Limitation of curren...
Strategy to tackle the obstacles of the DMD model
 Map the environment and identify specific areas of POs strategic inter...
POs and Industry
 Benefit/Risk Study in Duchenne Muscular Dystrophy (DMD) regarding pulmonary
therapies in the disease wi...
POs and Academia
 TREAT-NMD It started some years ago as a network of registries and now is involved in
the biggest proje...
POs and Regulators
 European Medicine Agency (EMA) As Draft Guideline on the clinical investigation of
medicinal products...
New models of patient involvement
 New models of drug development
• Patient driven research consortiums, Cross disease co...
Upcoming SlideShare
Loading in …5
×

Patient interactions between Industry, HTAs, Academia & Regulators

1,152 views

Published on

Dimitrios Athanasiou UPPMD
Increasing patient involvment
Patient interactions between Industry, HTAs, Academia & Regulators

Published in: Health & Medicine
  • Be the first to comment

  • Be the first to like this

Patient interactions between Industry, HTAs, Academia & Regulators

  1. 1. “Patient interactions between Industry, HTAs, Academia & Regulators” The United Parent Projects Duchenne Muscular Dystrophy Model Dimitrios Athanasiou, UPPMD Board member & EMA expert patient
  2. 2. POs Placement in the Medical Development equation  Grey areas of POs relations with the industry in the past • Lack of trust from all sides increases the complexity of the environment and delays drug development  Almost all other stakeholders have a clear code of conduct and compliance regulations * • POs need a professional approach and a specific frame of conduct with the other stakeholders. • Legal & compliance advice is most needed in POs.  There is great need for more directive towards patient involvement • This can only be achieved in an organized and transparent environment  POs need to have a clear position in the medical development equation • We need to be clear about our interests , our positioning and find effective ways to tackle possible challenges in the equation with the other stakeholders * EMAs code of conduct, EFPIA code, EURORDIS code of practise ,HTAi code of conduct etc
  3. 3.  Lack of knowledge and skilled expert patients  Lack of transparency and a common code of conduct  Limitation of current models for rare and ultra rare diseases  Limitation in understanding the “bigger” picture and long-term stategy Limitations and obstacles at the national and international level Duchenne Muscular Dystrophy (DMD) is one of the most common, devastating and lethal genetic disease of childhood. DMD occurs in ~1:3500 male births world-wide with no treatment or cure and life expectancy between late 20s and early 30s. What is Duchenne Muscular Dystrophy (DMD)
  4. 4. Strategy to tackle the obstacles of the DMD model  Map the environment and identify specific areas of POs strategic interest (Academic research, industry, regulatory work, training, venture capital & funding etc.)  Identify key stakeholders per area and place specific goals  Define which POs of the community are more effective per area  Help develop new organizations internationally and integrate them, they will be a constant stream of highly skilled patient advocates  Develop working groups and a group leader with various umbrella organization PO reps  Identify highly skilled patient advocates specialized in different areas of interest within the umbrella organization and train new specialized patient advocates per area  Manage possible conflicts by developing alternative skilled patient advocates per area  Distribute knowledge and best practises under the umbrella organization
  5. 5. POs and Industry  Benefit/Risk Study in Duchenne Muscular Dystrophy (DMD) regarding pulmonary therapies in the disease with Santhera and Parent Project.  Decode Duchenne PPMD Launches Next Phase of Genetic Testing Program, Decode Duchenne in collaboration with BioMarin Pharmaceutical, PTC Therapeutics, & Sarepta Therapeutics is a nationwide program to assist individuals with Duchenne muscular dystrophy in accessing genetic testing, interpretation, and counseling.  DMD Patient Advocacy Group (PAG) advisory board with PTC looking at challenges and solutions in DMD, best practices and knowledge transfer.  NICE accreditation on Duchenne guidelines as produced by the highest standards and we are in constant contact offering real life expertise for Qualis and receiving pharma economics advice for our projects POs and HTAs
  6. 6. POs and Academia  TREAT-NMD It started some years ago as a network of registries and now is involved in the biggest project leader in Neuromuscular diseases with offshore activities. Patient Reps are always in the Board of Directors and the Steering Committee • Since 2007 the network's focus has been on the development of tools that industry, clinicians and scientists need to bring novel therapeutic approaches and on establishing best-practice care for neuromuscular patients worldwide.“  RD CONNECT connects, databases, biobanks and ‘clinical bio-informatics’ for rare diseases  DMD IMAGING works on development of new Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) technologies for Skeletal Muscle and as a biomarker for DMD therapeutic development  PPMD and LEIDEN partnership created a breakthrough Exon skipping technology for DMD  DMD Exo-Skeleton International Project works on how technology can assist DMD patient mobility
  7. 7. POs and Regulators  European Medicine Agency (EMA) As Draft Guideline on the clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy  US Food & Drug Administration (FDA) Draft Guidance on Duchenne PPMD and a broad coalition of stakeholders has submitted the first-ever patient advocacy-initiated draft guidance for a rare disease to the FDA to help accelerate development and review of potential therapies for Duchenne muscular dystrophy. • More than 80 representatives of the Duchenne participated in seven working groups that met over the past six months to draft the guidance.  Common points of " Interest " by the regulatory authorities for POs • Consulting, Strategic Advisory Work for example participation in advisory boards, steering committees etc with or without remuneration and • POs funding should be declared! Reference http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000178.jsp http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2014/11/WC500177570.pdf http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/landing/experts.jsp
  8. 8. New models of patient involvement  New models of drug development • Patient driven research consortiums, Cross disease consortiums, Patient owned registries, Post Marketing Registries (PMRs) , Patient Reported Outcomes (PROs) , Patient Reported Outcome Measures (PROMs) etc.  New models of drug development financing • Philanthropic venture capital, hedge funds, crowdfunding, etc.  Non profit Pharmas and Non Profit Contract Research Organizations (CROs) • Drug repositioning and DMD Mapping project with a non profit Pharma (Data is owned from POs)  Hybrid models of Intellectual property (IP) ownership and/or animal model ownership • Leiden Exon skipping 51 and DMD mouse The Future

×